Therapy of spondyloarthritides

Advances in Experimental Medicine and Biology

Volumn 649, Issue , 2009, Pages 133-147

  Braun, Jürgen ^a  

^a RHEUMAZENTRUM RUHRGEBIET   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HLA B27 ANTIGEN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STEROID; SULFALAZINE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ANKYLOSING SPONDYLITIS; ARTHRITIS; ARTICLE; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DIAGNOSTIC IMAGING; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENTERITIS; ENTHESITIS; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; IRIDOCYCLITIS; KINESIOTHERAPY; LABORATORY TEST; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT EDUCATION; PHYSICAL PERFORMANCE; PHYSIOTHERAPY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SPINAL PAIN; SPINE DISEASE; SPINE RADIOGRAPHY; SPONDYLOARTHROPATHY; TREATMENT DURATION; TREATMENT PLANNING; ULCERATIVE COLITIS; DRUG ANTAGONISM; HOSPITALIZATION; JOINT; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; SPINE; SPONDYLARTHRITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; HUMANS; JOINTS; SEVERITY OF ILLNESS INDEX; SPINE; SPONDYLARTHRITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70349562393     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-0298-6_10     Document Type: Article

References (92)

1. Braun J, Sieper J. Ankylosing spondylitis. The Lancet 2007; 369:1379-1390. (Pubitemid 46590387)
2. Zochling J, van der Heijde D, Burgos-Vargas R et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65(4):442-52.
3. Braun J, Davis J, Dougados M et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65(3):316-20. (Pubitemid 43268219)
4. Zochling J, Braun J. Assessments in ankylosing spondylitis. Best Pract Res Clin Rheumatol 2007; 21(4):699-712. (Pubitemid 47163603)
5. van der Heijde D, Bellamy N, Calin A et al. Assessments in ankylosing spondylitis working group. Preliminary core sets for endpoints in ankylosing spondylitis. J Rheumatol 1997; 24:2225-29. (Pubitemid 27474048)
6. van der Heijde D, Calin A, Dougados M et al. ASAS working group. Selection of instruments in the core set for DC-ART, SMARD, physical therapy and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS group. J Rheumatol 1999; 26:951-54. (Pubitemid 29195692)
7. Garrett S, Jenkinson T, Kennedy G et al. A new approach to defining disease status in ankylosing spondylitis: The Bath ankylosing spondylitis disease activity index (BASDAI). J Rheumatol 1994; 1:2286-91.
8. Calin A, Nakache J-P, Gueguen A et al. Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology 1999; 38:878-82. (Pubitemid 29507371)
9. Calin A, Garrett S, Whitelock H et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the bath ankylosing spondylitis functional index. J Rheumatol 1994; 21:2281-85.
10. Spoorenberg A, van der Heijde D, de Klerk E et al. A comparative study of the usefulness of the bath ankylosing spondylitis functional index and the dougados functional index in the assessment of ankylosing spondylitis. J Rheumatol 1999; 26:961-65. (Pubitemid 29195694)
11. Haywood KL, Garratt AM, Dawes PT. Patient-assessed health in ankylosing spondylitis: a structured review. Rheumatology 2005; 44:577-86. (Pubitemid 41508636)
12. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003; 62:127-32. (Pubitemid 36135387)
13. Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359:1187-93. (Pubitemid 34304258)
14. Dagfinrud H, Vollestad NK, Loge JH et al. Fatigue in patients with ankylosing spondylitis: a comparison with the general population and associations with clinical and self-reported measures. Arthritis Rheum 2005; 53:5-11. (Pubitemid 40216345)
15. van Tubergen A, Coenen J, Landewé R et al. Assessment of fatigue in patients with ankylosing spondylitis: a psychometric analysis. Arthritis Rheum 2002; 47:8-16. (Pubitemid 34137338)
16. Jenkinson TR, Mallorie PA, Whitelock HC et al. Defining spinal mobility in ankylosing spondylitis (AS). The bath AS metrology index. J Rheumatol 1994; 21(9):1694-98. (Pubitemid 24285485)
17. Taylor HG, Wardle T, Beswich EJ et al. The relationship of clinical and laboratory measurements to radiological change in ankylosing spondylitis. Br J Rheumatol 1991; 30:330-35.
18. Creemers MCW, Franssen MJAM, van't Hof MA et al. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005; 64:127-29. (Pubitemid 40075289)
19. Calin A, Mackay K, Santos H et al. A new dimension to outcome: application of the bath ankylosing spondylitis radiology index. J Rheumatol 1999; 26:988-92. (Pubitemid 29195700)
20. Wanders AJ, Landewe RB, Spoorenberg A et al. What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the outcome measures in rheumatology clinical trials filter. Arthritis Rheum 2004; 50(8):2622-32. (Pubitemid 39062724)
21. Baraliakos X, Landewe R, Hermann KG et al. Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging. Ann Rheum Dis 2005; 64:730-34. (Pubitemid 40559300)
22. Braun J, Baraliakos X, Golder W et al. Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems. Ann Rheum Dis 2004; 63:1046-55. (Pubitemid 39120353)
23. Braun J, Baraliakos X, Golder W et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 2003; 48:1126-36. (Pubitemid 36418256)
24. Heuft-Dorenbosch L, Landewe R, Weijers R et al. Combining information obtained from magnetic resonance imaging and conventional radiographs to detect sacroiliitis in patients with recent onset inflammatory back pain. Ann Rheum Dis 2006; 65(6):804-8. (Pubitemid 43799182)
25. Balint PV, Kane D, Wilson H et al. Ultrasonography of entheseal insertions in the lower limb in spondyloarthropathy. Ann Rheum Dis 2002; 61:905-10.
26. D'Agostino MA, Said-Nahal R, Hacquard-Bouder C et al. Assessment of peripheral enthesitis in the spondyloarthropathies by ultrasonography combined with power doppler: a cross-sectional study. Arthritis Rheum 2003; 48:523-33. (Pubitemid 36278022)
27. Spoorenberg A, van der Heijde D, de Klerk E et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 1999; 26:980-84. (Pubitemid 29195698)
28. Anderson JJ, Baron G, van der Heijde D et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001; 44:1876-86. (Pubitemid 32758236)
29. Stone MA, Inman RD, Wright JG et al. Validation exercise of the ankylosing spondylitis assessment study (ASAS) group response criteria in ankylosing spondylitis patients treated with biologics. Arthritis Rheum 2004; 51:316-20. (Pubitemid 38725127)
30. Brandt J, Listing J, Sieper J et al. Development and preselection of criteria for short term improvement atter anti-TNFα treatment in ankylosing spondylitis. Ann Rheum Dis 2004; 63:1438-44. (Pubitemid 39433948)
31. Dougados M, Dijkmans B, Khan M et al. Conventional treatments for ankylosing spondylitis. Ann Rheum Dis 2002; 61(Suppl 3):iii40-50. (Pubitemid 35397344)
32. Kraag G, Stokes B, Groh J et al. The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis - a randomized controlled trial. J Rheumatol 1990; 17(2):228-33. (Pubitemid 20108228)
33. van Tubergen A, Landewe R, van der Heijde D et al. Combined spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 2001; 45(5):430-8. (Pubitemid 32979848)
34. Dagfinrud H, Kvien TK, Hagen KB. The Cochrane review of physiotherapy interventions for ankylosing spondylitis. J Rheumatol 2005; 32(10):1899-906. (Pubitemid 41429019)
35. Amor B, Dougados M, Mijiyawa M. Criteria of the classification of spondylarthropathies. Rev Rhum Mal Osteoartic 1990; 57(2):85-9.
36. Dougados M, Behier JM, Jolchine I et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 2001; 44(1):180-5. (Pubitemid 32113133)
37. Wanders A, Heijde D, Landewe R et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005; 52(6):1756-65. (Pubitemid 40852884)
38. Ward MM, Kuzis S. Medication toxicity among patients with ankylosing spondylitis. Arthritis Rheum 2002; 47(3):234-41. (Pubitemid 34627689)
39. Zochling J, Bohl-Buhler MH, Baraliakos X et al. Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis-a population-based survey. Clin Rheumatol 2006; [Epub ahead of print].
40. Dougados M, van der Linden S, Leirisalo-Repo M et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995; 38(5):618-27.
41. Chen J, Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2005(2):CD004800.
42. Braun J, Zochling J, Baraliakos X et al. Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis : a multicentre randomized controlled trial. Ann Rheum Dis 2006; 65(9):1147-53. (Pubitemid 44277387)
43. Chen J, Liu C. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2004(3):CD004524.
44. Gonzalez-Lopez L, Garcia-Gonzalez A, Vazquez-Del-Mercado M et al. Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial. J Rheumatol 2004; 31(8):1568-74. (Pubitemid 39006639)
45. Haibel H, Brandt HC, Song IH et al. Results of an open label pilot study with 20 mg methotrexate parenterally for the treatment of active anklyosing spondylitis. Ann Rheum Dis 2006; in press.
46. Haibel H, Rudwaleit M, Braun J. Six months open label trial of leflunomide in active ankylosing spondylitis. Ann Rheum Dis 2005; 64(1):124-6. (Pubitemid 40075288)
47. Van Denderen JC, Van der Paardt M, Nurmohamed MT et al. Double-blind, randomised, placebo-controlled study of leflunomide in the treatment of active ankylosing spondylitis. Ann Rheum Dis 2005; 64:1761-1764. (Pubitemid 41667152)
48. Kaltwasser JP, Nash P, Gladman D et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004; 50(6):1939-50. (Pubitemid 38725106)
49. Maksymowych WP, Jhangri GS, Fitzgerald AA et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 2002; 46(3):766-73. (Pubitemid 34214258)
50. Haibel H, Brandt J, Rudwaleit M et al. Treatment of active ankylosing spondylitis with pamidronate. Rheumatology (Oxford) 2003; 42(8):1018-20. (Pubitemid 37220983)
51. Huang F, Gu J, Zhao W et al. One-year open-label trial of thalidomide in ankylosing spondylitis. Arthritis Rheum 2002; 47(3):249-54. (Pubitemid 34627691)
52. Heiberg MS, Nordvag BY, Mikkelsen K et al. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study. Arthritis Rheum 2005; 52(8):2506-12. (Pubitemid 41117438)
53. van der Heijde D, Dijkmans B, Geusens P et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52(2):582-91. (Pubitemid 40216323)
54. Davis JC Jr, Van Der Heijde D, Braun J et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48(11):3230-6. (Pubitemid 37409337)
55. Calin A, Dijkmans BA, Emery P et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004; 63(12):1594-600. (Pubitemid 39573687)
56. van der Heijde D, Kivitz A, Schiff M et al. Adalimumab therapy results in significant reduction of signs and symptoms in subjects with ankylosing spondylitis: The ATLAS Trial. Arthritis Rheum 2006; 54:2136-46.
57. Braun J, Landewe R, Hermann KG et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 2006; 54(5):1646-52.
58. Baraliakos X, Davis J, Tsuji W. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor α receptor fusion protein etanercept. Arthritis Rheum 2005; 52:1216-23. (Pubitemid 40530129)
59. Haibel H, Rudwaleit M, Brandt HC et al. Adalimumab reduces spinal symptoms in active ankylosing spondylitis - clinical and magnetic resonance imaging results of a fifty-two week open label trial. Arthritis Rheum 2006; 54:678-81.
60. Sieper J, Baraliakos X, Listing J et al. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology (Oxford) 2005; 44:1525-30. (Pubitemid 41742469)
61. Baraliakos X, Brandt J, Listing J et al. Outcome of patients with active anklyosing spondylitis after 2 years of therapy with etanercept - clinical and magnetic resonance imaging data. Arthritis Res Ther 2005; 7(3):113.
62. Braun J, Baraliakos X, Brandt J et al. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) 2005; 44(5):670-6. (Pubitemid 41487242)
63. Davis JC, van der Heijde DM, Braun J et al. Efficacy and safety of up to 192 weeks of etanercepr therapy in patients with ankylosing spondylitis. Ann Rheum Dis 2007; [Epub ahead of print].
64. Braun J, Baraliakos X, Listing J et al. Persistent clinical efficacy and safety of anti-TNF{alpha} therapy with infliximab in patients with ankylosing spondylitis over 5 years - evidence for different types of response. Ann Rheum Dis 2007; [Epub ahead of print].
65. Baraliakos X, Listing J, Brandt J et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 2005; 7(3):R439-44.
66. Brandt J, Kariouzov A, Listing J et al. Six months results of a German double-blind placebo controlled clinical trial of etanercept in active ankylosing spondylitis. Arthritis Rheum 2003; 48(6):1667-75. (Pubitemid 36682375)
67. Baraliakos X, Listing J, Rudwaleit M et al. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the TNF-α antibody infliximab. Ann Rheum Dis 2005; 64(10):1462-6. (Pubitemid 41623858)
68. Baraliakos X, Listing J, Brandt J et al. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNf-α antibody infliximab. Rheumatology (Oxford) 2007; [Epub ahead of print].
69. Allali F, Breban M, Porcher R et al. Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor α. Ann Rheum Dis 2003; 62:347-49. (Pubitemid 36363442)
70. Brandt J, Haibel H, Reddig J et al. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. J Rheumatol 2002; 29(1):118-22. (Pubitemid 34041867)
71. Brandt J, Khariouzov A, Listing J et al. Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept. J Rheumatol 2004; 31(3):531-8. (Pubitemid 38337615)
72. Feldman SR, Gordon KB, Bala M et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol 2005; 152(5):954-60. (Pubitemid 40704936)
73. Mease PJ, Kivitz AJ, Burch FX et al. Etanercept treatment of psoriatic arthritis: safety, efficacy and effect on disease progression. Arthritis Rheum 2004; 50(7):2264-72. (Pubitemid 38924405)
74. Mease P, Gladman D, Ritchlin C et al. Adalimumab therapy in patients with psoriatic arthritis: 24-week results of a phase III study. Arthritis Rheum 2004; 50:4097.
75. Antoni C, Krueger GG, de Vlam K et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; [Epub ahead of print].
76. Marzo-Ortega H, McGonagle D, O'Connor P et al. Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. Ann Rheum Dis 2003; 62(1):74-6. (Pubitemid 36005801)
77. Braun J, Baraliakos X, Listing J et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007; 57(4):639-47. (Pubitemid 46764055)
78. Sandborn WJ, Hanauer SB, Katz S et al. Etanercept for active crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121(5):1088-94. (Pubitemid 33022088)
79. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359(9317):1541-9. (Pubitemid 34621118)
80. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353(23):2462-76. (Pubitemid 41770166)
81. Braun J, Baraliakos X, Listing J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005; 52(8):2447-51. (Pubitemid 41117431)
82. Guignard S, Gossec L, Salliot C et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis 2006; 65(12):1631-4. Epub 2006. (Pubitemid 44799677)
83. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007; 56(10):3248-52. (Pubitemid 47585419)
84. Braun J, Davis J, Dougados M et al. First update of the international ASAS consensus statement for the use of anri-tnf agents in patients with ankylosing spondylitis. Ann Rheum Dis 2005; [Epub ahead of print].
85. Rudwaleit M, Listing J, Brandt J et al. Prediction of a major clinical-response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004; 63(6):665-70. (Pubitemid 38658395)
86. Tan AL, Marzo-Ortega H, O'Connor P et al. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis 2004; 63(9):1041-5. (Pubitemid 39120352)
87. Haibel H, Rudwaleit M, Listing J et al. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 2005; 64(2):296-8. (Pubitemid 40193630)
88. Kobelt G, Andlin-Sobocki P, Brophy S et al. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). Rheumatology (Oxford) 2004; 43(9):1158-66. (Pubitemid 39232822)
89. van der Heijde D, Han C, Devlam K et al. Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: Results from a randomized, placebo-controlled trial. Arthritis Rheum 2006; 55(4):569-574. (Pubitemid 44289876)
90. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984; 27(4):361-8. (Pubitemid 14134775)
91. Haibel H, Rudwaleit M, Listing J et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroilitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum. 2008; 58(7):1981-1991. (Pubitemid 351988090)
92. van Tubergen A, van der Heijde D, Anderson J et al. Comparison of statistically derived ASAS improvement criteria for ankylosing spondylitis with clinically relevant improvement according to an expert panel. Ann Rheum Dis. 2003; 62(3):215-221. (Pubitemid 36238083)